634 RESULTS FROM THE BARRETT'S OESOPHAGUS TRIAL 3 (BEST3): A RANDOMISED CONTROLLED TRIAL COMPARING THE CYTOSPONGE™-TFF3 TEST WITH USUAL CARE TO IDENTIFY OESOPHAGEAL PRECANCER IN PRIMARY CARE PATIENTS WITH CHRONIC GASTROESOPHAGEAL REFLUX (2020)
Attributed to:
Oesophago-gastric adenocarcinoma: understanding disease pathogenesis and applications to earlier diagnosis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0016-5085(20)31020-9
Publication URI: http://dx.doi.org/10.1016/s0016-5085(20)31020-9
Type: Journal Article/Review
Parent Publication: Gastroenterology
Issue: 6